What is it about?

It summarizes lessons learned from the use of a structured framework approach in assessing benefit-risk profile of new therapeutics for Marketing Authorization Applications

Featured Image

Why is it important?

Sponsors can apply these approaches to incorporate benefit-risk assessments into their marketing authorization applications. Further shared learning and benchmarking among the pharmaceutical industry will be necessary to further advance the science and practice of benefit-risk assessment.

Perspectives

Further shared learnings and benchmarking among the pharmaceutical industry will be necessary to further advance the science and practice of benefit-risk assessment.

JuAn Wang
Eli Lilly and Co

Read the Original

This page is a summary of: Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications, Therapeutic Innovation & Regulatory Science, July 2016, SAGE Publications,
DOI: 10.1177/2168479016656898.
You can read the full text:

Read

Contributors

The following have contributed to this page